Business
NuLife Announces Plan to Commercialize Lead Compound in Ecuador
NuLife Announces Plan to Commercialize Lead Compound in Ecuador.
About this update from Gulf West Security Network Inc.
[{"type":"text","content":"\nNuLife Announces Plan to Commercialize Lead Compound in Ecuador\n\nNuLife Announces Plan to Commercialize Lead Compound in Ecuador\n\n\nLyophilized Cytokine Concentrated Plasma (lyoCCP) Aids Healing of Wounds\n\nNEWPORT BEACH, CA--(Marketwired - September 26, 2017) - NuLife Sciences (OTCQB: NULF) through the company's wholly-owned subsidiary, NuLife Medical, today announced plans to commercialize their lead compound, lyophilized Cytokine Concentrated Plasma (lyoCCP) in Ecuador.The lyoCCP product is produced utilizing the NuLife Technique, the proprietary platform being developed by NuLife Sciences. The proprietary product has shown impressive results in aiding the healing of wounds that have been resistant to closure with traditional methods. An observational study was conducted earlier this year, showing impressive results in ten subjects. A larger study is planned in the coming weeks and months.The worldwide wound care market is expected to be in excess of $20 billion by 2022. In fact, the worldwide incidence of all types of wounds ranges between 2% and 6%. These wounds represent a significant health risk, negatively impacting the quality of life for patients. In addition, they are very costly to healthcare systems.\"We are pleased with the study results and look forward to making an impact on the wound care market with our lyoCCP product,\" said John Hollister, NuLife Sciences Chief Executive Officer. \"We have received tremendous support for this product from the medical community in Ecuador and the response from patients has been overwhelming. We see a significant opportunity in this market to commercialize this product, creating additional value for our shareholders.\"About NuLife SciencesNuLife Sciences Inc. is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including wound care, organ and tissue transplants, regenerative medicine, and cell therapy. NuLife Sciences Inc. operates through two wholly-owned subsidiaries, NuLife Medical and NuLife BioMed. NuLife Medical utilizes a patent protected and unique proprietary method referred to as the \"NuLife Technique\" for the treatment of chronic wounds that resist closure or healing, such as diabetic foot ulcers and abrasions. NuLife Medical is currently applying the treatment to...